VS TR 2x Long VIX Futures ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

ProShares Ultra VIX Short-Term Futures

T-REX 2X Inverse Tesla Daily Target ETF

iPath S&P 500 VIX ST Futures ETN

Bank Of Montreal

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Financial Bear 3X Shar

Direxion Daily TSLA Bull 1.5X Shares

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

GraniteShares 2x Long AMZN Daily ETF

GraniteShares 1.5x Long Coinbase Daily ETF

GraniteShares 1.5x Long META Daily ETF

Guggenheim Solar ETF

VS TR -1x Short VIX Futures ETF

Volatility Shares Trust 2x Ether ETF

AXS 2X Innovation ETF

Regulus Therapeutics Inc. Common Stock

Jeffs' Brands Ltd Ordinary Shares

WW International Inc. Common Stock

Petros Pharmaceuticals Inc. Common Stock

LogicMark Inc. Common Stock

Sharps Technology Inc. Common Stock

Nvni Group Limited Ordinary Shares

New Gold Inc.

Altisource Portfolio Solutions S.A. Common Stock

Urgent.ly Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Snap Inc. Class A Common Stock

Super Micro Computer Inc. Common Stock

AtriCure Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

Autonomix Medical Inc. Common Stock

Plug Power Inc. Common Stock

Hillenbrand Inc Common Stock

First Solar Inc. Common Stock

Hertz Global Holdings Inc Common Stock

Click here to get full coverage on Novartis Pays 274% Premium in $1.7B Regulus Therapeutics Acquisition for ADPKD Drug - Stock Titan

Novartis Pays 274% Premium in $1.7B Regulus Therapeutics Acquisition for ADPKD Drug  Stock Titan

Novartis Pays 274% Premium in $1.7B Regulus Therapeutics Acquisition for ADPKD Drug - Stock Titan

Click here to get full coverage on Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG  PR Newswire

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire

Click here to get full coverage on RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - Business Wire

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders  Business Wire

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - Business Wire

Click here to get full coverage on Regulus Therapeutics (RGLS) to be Acquired by Novartis (NVS) for $7 Per Share - StreetInsider

Regulus Therapeutics (RGLS) to be Acquired by Novartis (NVS) for $7 Per Share  StreetInsider

Regulus Therapeutics (RGLS) to be Acquired by Novartis (NVS) for $7 Per Share - StreetInsider

Click here to get full coverage on Novartis to acquire Regulus for $7.00 a share in cash (RGLS:NASDAQ) - Seeking Alpha

Novartis to acquire Regulus for $7.00 a share in cash (RGLS:NASDAQ)  Seeking Alpha

Novartis to acquire Regulus for $7.00 a share in cash (RGLS:NASDAQ) - Seeking Alpha

Click here to get full coverage on Regulus Therapeutics (RGLS): A Promising Penny Stock for 2025 - GuruFocus

Regulus Therapeutics (RGLS): A Promising Penny Stock for 2025  GuruFocus

Regulus Therapeutics (RGLS): A Promising Penny Stock for 2025 - GuruFocus

Click here to get full coverage on RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - The Joplin Globe

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders  The Joplin Globe

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - The Joplin Globe

Click here to get full coverage on $RGLS stock is up 22% today. Here's what we see in our data. - Nasdaq

$RGLS stock is up 22% today. Here's what we see in our data.  Nasdaq

$RGLS stock is up 22% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg.com

Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS)  Bloomberg.com

Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg.com

Click here to get full coverage on Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Yahoo Finance

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?  Yahoo Finance

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Yahoo Finance

Click here to get full coverage on Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million  Benzinga

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga

Click here to get full coverage on SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS - PR Newswire

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS  PR Newswire

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS - PR Newswire

Click here to get full coverage on Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus

Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R  GuruFocus

Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus

Click here to get full coverage on Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders  Business Wire

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Click here to get full coverage on Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates  PR Newswire

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire

Click here to get full coverage on Regulus Therapeutics Enters into Agreement to be Acquired by Nov - GuruFocus

Regulus Therapeutics Enters into Agreement to be Acquired by Nov  GuruFocus

Regulus Therapeutics Enters into Agreement to be Acquired by Nov - GuruFocus

Click here to get full coverage on Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)  PR Newswire

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Click here to get full coverage on Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - PR Newswire

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)  PR Newswire

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - PR Newswire

Click here to get full coverage on Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PR Newswire

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates  PR Newswire

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PR Newswire

Click here to get full coverage on Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher  Benzinga

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga

Click here to get full coverage on Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)  PR Newswire

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Click here to get full coverage on Regulus Announces Merger Agreement with Novartis - TipRanks

Regulus Announces Merger Agreement with Novartis  TipRanks

Regulus Announces Merger Agreement with Novartis - TipRanks

Click here to get full coverage on Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Yahoo Finance

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now  Yahoo Finance

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Yahoo Finance

Click here to get full coverage on Should You Buy Regulus (RGLS) After Golden Cross? - Yahoo

Should You Buy Regulus (RGLS) After Golden Cross?  Yahoo

Should You Buy Regulus (RGLS) After Golden Cross? - Yahoo

Click here to get full coverage on Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PR Newswire

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates  PR Newswire

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PR Newswire

Click here to get full coverage on Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance

Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently  Yahoo Finance

Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance

Click here to get full coverage on RGLS stock touches 52-week high at $2.91 amid market optimism By Investing.com - Investing.com South Africa

RGLS stock touches 52-week high at $2.91 amid market optimism By Investing.com  Investing.com South Africa

RGLS stock touches 52-week high at $2.91 amid market optimism By Investing.com - Investing.com South Africa

Click here to get full coverage on Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring  RagingBull

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull

Click here to get full coverage on Novartis (NVS) to Acquire Regulus Therapeutics for $0.8B - GuruFocus

Novartis (NVS) to Acquire Regulus Therapeutics for $0.8B  GuruFocus

Novartis (NVS) to Acquire Regulus Therapeutics for $0.8B - GuruFocus

Click here to get full coverage on microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan

microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit  Stock Titan

microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan

Click here to get full coverage on Promising Penny Stocks To Consider In April 2025 - simplywall.st

Promising Penny Stocks To Consider In April 2025  simplywall.st

Promising Penny Stocks To Consider In April 2025 - simplywall.st

Click here to get full coverage on With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance

With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns  Yahoo Finance

With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance

Click here to get full coverage on Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - PR Newswire

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit  PR Newswire

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - PR Newswire

Click here to get full coverage on Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)  PR Newswire

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Click here to get full coverage on Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq

Wells Fargo Upgrades Regulus Therapeutics (RGLS)  Nasdaq

Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq

Click here to get full coverage on New Analyst Forecast: $RGLS Given 'Overweight' Rating - Nasdaq

New Analyst Forecast: $RGLS Given 'Overweight' Rating  Nasdaq

New Analyst Forecast: $RGLS Given 'Overweight' Rating - Nasdaq

Click here to get full coverage on Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan

Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial  Stock Titan

Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan

Click here to get full coverage on Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - PR Newswire

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference  PR Newswire

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - PR Newswire

Click here to get full coverage on What Makes Regulus (RGLS) a New Buy Stock - Nasdaq

What Makes Regulus (RGLS) a New Buy Stock  Nasdaq

What Makes Regulus (RGLS) a New Buy Stock - Nasdaq

Click here to get full coverage on Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance

Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00  Yahoo Finance

Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance

Click here to get full coverage on Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - Yahoo Finance

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks  Yahoo Finance

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - Yahoo Finance

Click here to get full coverage on Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider

Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD  StreetInsider

Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider

Click here to get full coverage on Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha

Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ)  Seeking Alpha

Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha

Click here to get full coverage on Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - Stock Titan

Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial  Stock Titan

Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - Stock Titan

Click here to get full coverage on Press Release Distribution & PR Platform - ACCESS Newswire

Press Release Distribution & PR Platform  ACCESS Newswire

Press Release Distribution & PR Platform - ACCESS Newswire

Click here to get full coverage on Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?  Yahoo

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo

Click here to get full coverage on CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - simplywall.st

CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares  simplywall.st

CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - simplywall.st

Click here to get full coverage on Regulus: Q4 Earnings Snapshot - MySA

Regulus: Q4 Earnings Snapshot - MySA

Click here to get full coverage on Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PR Newswire

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer  PR Newswire

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PR Newswire

Click here to get full coverage on Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen - StreetInsider

Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen  StreetInsider

Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen - StreetInsider

Click here to get full coverage on Regulus heads to phase III after more positive kidney disease data - BioWorld MedTech

Regulus heads to phase III after more positive kidney disease data  BioWorld MedTech

Regulus heads to phase III after more positive kidney disease data - BioWorld MedTech

Click here to get full coverage on Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data - Yahoo Finance

Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data  Yahoo Finance

Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data - Yahoo Finance

Click here to get full coverage on Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T - GuruFocus

Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T  GuruFocus

Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T - GuruFocus

Click here to get full coverage on Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus

Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R  GuruFocus

Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus

Click here to get full coverage on Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - PR Newswire

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences  PR Newswire

Regulus Therapeutics Inc (RGLS)

Price Chart

Key Statistics

Technicals

About RGLS

Latest News

Novartis Pays 274% Premium in $1.7B Regulus Therapeutics Acquisition for ADPKD Drug - Stock Titan

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - Business Wire

Advanced Charts

Top Gainers

Top Losers